462 related articles for article (PubMed ID: 26358690)
1. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.
Chang M; Yu Z; Shenker A; Wang J; Pursley J; Byon W; Boyd RA; LaCreta F; Frost CE
J Clin Pharmacol; 2016 May; 56(5):637-45. PubMed ID: 26358690
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.
Wang X; Tirucherai G; Marbury TC; Wang J; Chang M; Zhang D; Song Y; Pursley J; Boyd RA; Frost C
J Clin Pharmacol; 2016 May; 56(5):628-36. PubMed ID: 26331581
[TBL] [Abstract][Full Text] [Related]
3. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
Frost CE; Song Y; Shenker A; Wang J; Barrett YC; Schuster A; Harris SI; LaCreta F
Clin Pharmacokinet; 2015 Jun; 54(6):651-62. PubMed ID: 25573421
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.
Yamahira N; Frost C; Fukase H; Yu Z; Wang J; Pursley J; LaCreta F; Hiraoka M
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):564-73. PubMed ID: 24725442
[TBL] [Abstract][Full Text] [Related]
5. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.
Upreti VV; Wang J; Barrett YC; Byon W; Boyd RA; Pursley J; LaCreta FP; Frost CE
Br J Clin Pharmacol; 2013 Dec; 76(6):908-16. PubMed ID: 23488672
[TBL] [Abstract][Full Text] [Related]
6. Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.
Frost C; Garonzik S; Shenker A; Barrett YC; LaCreta F
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):974-984. PubMed ID: 34342172
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.
Frost C; Shenker A; Gandhi MD; Pursley J; Barrett YC; Wang J; Zhang D; Byon W; Boyd RA; LaCreta F
Br J Clin Pharmacol; 2014 Oct; 78(4):877-85. PubMed ID: 24697979
[TBL] [Abstract][Full Text] [Related]
8. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
9. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
[TBL] [Abstract][Full Text] [Related]
10. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
Barrett YC; Wang J; Song Y; Pursley J; Wastall P; Wright R; Lacreta F; Frost C
Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism.
Byon W; Sweeney K; Frost C; Boyd RA
CPT Pharmacometrics Syst Pharmacol; 2017 May; 6(5):340-349. PubMed ID: 28547774
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban after oral and intravenous administration to cats.
Myers JA; Wittenburg LA; Olver CS; Martinez CM; Bright JM
Am J Vet Res; 2015 Aug; 76(8):732-8. PubMed ID: 26207972
[TBL] [Abstract][Full Text] [Related]
13. Validation of apixaban anti-factor Xa assay and impact of body weight.
Wasan SM; Feland N; Grant R; Aston CE
Thromb Res; 2019 Oct; 182():51-55. PubMed ID: 31450008
[TBL] [Abstract][Full Text] [Related]
14. The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study.
Garonzik S; Byon W; Myers E; Li X; Marchisin D; Murthy B
Am J Cardiovasc Drugs; 2019 Dec; 19(6):561-567. PubMed ID: 31030414
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Frost C; Nepal S; Wang J; Schuster A; Byon W; Boyd RA; Yu Z; Shenker A; Barrett YC; Mosqueda-Garcia R; Lacreta F
Br J Clin Pharmacol; 2013 Nov; 76(5):776-86. PubMed ID: 23451769
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
Bookstaver DA; Sparks K; Pybus BS; Davis DK; Marcsisin SR; Sousa JC
Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
[TBL] [Abstract][Full Text] [Related]
17. Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions.
Kubisz P; Stanciakova L; Dobrotova M; Samos M; Mokan M; Stasko J
Curr Drug Metab; 2017; 18(7):609-621. PubMed ID: 28440204
[TBL] [Abstract][Full Text] [Related]
18. Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.
Vakkalagadda B; Frost C; Byon W; Boyd RA; Wang J; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Am J Cardiovasc Drugs; 2016 Apr; 16(2):119-27. PubMed ID: 26749408
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
[TBL] [Abstract][Full Text] [Related]
20. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
